Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Basit Öğe Kaydı
dc.contributor.authorKahraman, Seda
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorÖztürk, Akın
dc.contributor.authorİşleyen, Zehra Sucuoğlu
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned2024-04-24T16:24:04Z
dc.date.available2024-04-24T16:24:04Z
dc.date.issued2024
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri, İç Hastalıklar Anabilim Dalıen_US
dc.description.abstractCentral nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood-brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM. It is important to update the clinical and pathological factors reflected in the survival with real-life data. A multi-center, retrospective database of 306 patients diagnosed with driver mutant NSCLC and initially presented with BM between between November 2008 and September 2022 were analyzed. The median progression-free survival (mPFS) was 12.25 months (95% CI, 10-14.5). While 254 of the patients received tyrosine kinase inhibitor (TKI), 51 patients received chemotherapy as first line treatment. The median intracranial PFS (iPFS) was 18.5 months (95% CI, 14.8-22.2). The median overall survival (OS) was 29 months (95% CI, 25.2-33.0). It was found that having 3 or less BM and absence of extracranial metastases were significantly associated with better mOS and iPFS. The relationship between the size of BM and survival was found to be non-significant. Among patients with advanced NSCLC with de novo BM carrying a driver mutation, long-term progression-free and overall survival can be achieved with the advent of targeted agents with high CNS efficacy with more conservative and localized radiotherapy modalities.en_US
dc.identifier.citationKahraman, S., Karakaya, S., Kaplan, M. A., Göksu, S. S., Öztürk, A., İşleyen, Z. S. ve diğerleri. (2024). Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases. Scientific Reports, 14(1), 1-13.
dc.identifier.doi10.1038/s41598-024-56046-w
dc.identifier.issn2045-2322
dc.identifier.issue1en_US
dc.identifier.pmid38461209
dc.identifier.scopus2-s2.0-85187188671
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1038/s41598-024-56046-w
dc.identifier.urihttps://hdl.handle.net/11468/16444
dc.identifier.volume14en_US
dc.identifier.wosWOS:001185505600041
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofScientific Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncogene-driven advanced non-small cell lung canceren_US
dc.subjectDe novo brain metastasesen_US
dc.subjectSurvival related parametersen_US
dc.titleTreatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesen_US
dc.titleTreatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.pdf
Boyut:
1.35 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu